Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes

Journal of Medical Virology

Volumn 81, Issue 2, 2009, Pages 271-277

  Sandri, Maria Teresa ^a   Riggio, Daniela ^a   Salvatici, Michela ^a   Passerini, Rita ^a   Zorzino, Laura ^a   Boveri, Sara ^a   Radice, Davide ^a   Spolti, Noemi ^a   Sideri, Mario ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cervical lesion; Genotyping; HPV; HPV types prevalence

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CARCINOGENESIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; AGED; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PATHOLOGY; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

VIRUS DNA;

EID: 61749087215     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21382     Document Type: Article

References (27)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Morono V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide prospective. J Natl Cancer Inst 87:796-802.
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
3. Castle PE, Solomon D, Schiffman M, Wheeler CM. 2005. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal ormild cytologic abnormalities. J Natl Cancer Inst 97:1066-11071.
4. Castle PE, Sadorra M, Garcia F, Holladay EB, Kornegay J. 2006. Pilot study of a commercialized human papillomavirus genotyping assay: Comparison of HPV risk group to cytology and histology. J Clin Microbiol 44:3915-3917.
5. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. 2007. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 197:356.e1-356.e6.
6. Castle PE, Gracitt PE, Solomon D, Wheeler CM, Schiffmann M. 2008. Comparison of Linear Array an Line Blot Assay for detection of human papillomavirus and disgnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 46:109-117.
7. Clifford GM, Smith JS, Aguado T, Franceschi S. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 89:101-105.
8. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. 2005. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomavirus. Lancet Oncol 6:204.
9. Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, Valloncini B, Manca N. 2007. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 125:176-182.
10. Goodman LA, Kruskal WH. 1972. Measures of association for cross-classification IV. J Am Statist Assoc 67:415-421.
11. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. 2000. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92:464-474.
12. Jonckheere AR. 1954. A distribution-free k-sample test against ordered alternatives. Biometrika 41:133-145.
13. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:1072-1079.
14. Laconi S, Greco M, Pellegrini-Bettoli P, Pani P, Laconi E, Rais M. 2000. Detection and genetic typing of human papillomavirus in cervical biopsies in Cagliari Province. Pathologica 92:236-240.
15. Munoz N, Bosch FX, de Sanjose S, Horrero R, Castellague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
16. Prétet JL, Jacquard AC, Carcopino X, Monnier-Benoit S, Averous G, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D, EDITH Study Group. 2008. Human papillomavirus (HPV) genotype distribution in high-grade cervical lesions (CIN2/3) in France: EDITH study. Int J Cancer 122:424-427.
17. Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M. 2006. Comparison of the Digene HC2 assay and the Roche AMPLICOR Human Papillomavirus Test for the detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 44:2141-2146.
18. Sasagawa T, Basha W, Yamazaki H, Inoue M. 2001. High risk and multiple human papillomavirus infections associated with abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 10:45-52.
19. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84.
20. Terpstra TJ. 1952. The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indag Math 14:327-333.
21. van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn LJ, van den Tweel J. 2002. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 156:158-164.
22. Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, Musiani M, Zerbini ML. 2008. Correlation of high-risk papilloma virus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol 80:1434-1440.
23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer world-wide. J Pathol 189:12-19.
24. Wright TC, Schiffman M. 2003. Adding a test for human papillomavirus DNA to cervical cancer screening. N Engl J Med 348:489-490.
25. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ. 2004. HPV testing and monitoring of women after treatment of CIN 3: Review of the literature and meta-analysis. Obstet Gynecol Surv 59:543-553.
26. Zuna RE, Allen RA, Moore WE, Lu Y, Mattu R, Dunn ST. 2007. Distribution of HPV genotypes in 282 women with cervical lesions: Evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol 20:167-174.
27. Zur Hausen H. 2002. Papillomaviruses and cancer: From basic to clinical application. Nat Rev Cancer 2:342-350.